European journal of neurology · 2025
Efficacy and Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis.
СтатьяМетаанализСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Stefanou Maria-Ioanna, Chatziralli Irini, Lambadiari Vaia, Mengel Annerose, Foska Aikaterini, Chondrogianni Maria, Bakola Eleni, Tsalouchidou Panagiota-Eleni, Mitsikostas Dimos D, Siasos Gerasimos, Ziemann Ulf, Tsivgoulis Georgios
Аннотация
BACKGROUND: Repurposing glucagon-like peptide-1 (GLP-1) and GIP/GLP-1 receptor agonists (RAs) for idiopathic intracranial hypertension (IIH) represents an attractive alternative to current treatments, supported by evidence of potent metabolic effects and reductions in cerebrospinal fluid secretion and intracranial pressure in vivo.
METHODS: We evaluated the safety and efficacy of GLP-1 RAs and GIP/GLP-1 RAs in IIH. MEDLINE and Scopus databases were searched for randomized-controlled trials (RCT), non-randomized clinical trials, or registries in adults with IIH.
RESULTS: Two clinical trials (one RCT and one non-randomized case-control) and two registries, comprising 1550 IIH patients (768 receiving GLP-1 or GIP/GLP-1 RAs) were included. Compared with standard-of-care, GLP-1 or GIP/GLP-1 RAs were associated with a significantly lower risk of papilledema (RR: 0.25; 95% CI: 0.15-0.43; p < 0.01) and visual disturbances or blindness (RR: 0.41; 95% CI: 0.18-0.92; p = 0.03), and a near-significant trend toward reduced headache risk (RR: 0.61; 95% CI: 0.34-1.07; p = 0.08). Additionally, GLP-1 RAs significantly reduced monthly headache days at 3 months (MD = -3.64; 95% CI: -6.26 to -1.03; p < 0.01) and at the end of follow-up (MD = -4.82; 95% CI: -8.80 to -0.85; p = 0.02). No association was detected between GLP-1 RAs and body mass index. No serious adverse events or treatment discontinuations were reported; mild gastrointestinal adverse events and nausea occurred in 88% (95% CI: 0.46-1.00) of GLP-1 RA-treated patients.
CONCLUSIONS: GLP-1 and dual GIP/GLP-1 RAs are associated with a significantly lower risk of papilledema and visual disturbances or blindness and a lower headache risk compared with standard-of-care. Additionally, GLP-1 RAs significantly reduce the monthly headache burden. Well-designed RCTs are needed to robustly evaluate the effects of GLP-1 and GIP/GLP-1 RAs in IIH, which likely extend beyond their weight-loss-inducing properties.
TRIAL REGISTRATION: PROSPERO registration ID: CRD42025650082.
METHODS: We evaluated the safety and efficacy of GLP-1 RAs and GIP/GLP-1 RAs in IIH. MEDLINE and Scopus databases were searched for randomized-controlled trials (RCT), non-randomized clinical trials, or registries in adults with IIH.
RESULTS: Two clinical trials (one RCT and one non-randomized case-control) and two registries, comprising 1550 IIH patients (768 receiving GLP-1 or GIP/GLP-1 RAs) were included. Compared with standard-of-care, GLP-1 or GIP/GLP-1 RAs were associated with a significantly lower risk of papilledema (RR: 0.25; 95% CI: 0.15-0.43; p < 0.01) and visual disturbances or blindness (RR: 0.41; 95% CI: 0.18-0.92; p = 0.03), and a near-significant trend toward reduced headache risk (RR: 0.61; 95% CI: 0.34-1.07; p = 0.08). Additionally, GLP-1 RAs significantly reduced monthly headache days at 3 months (MD = -3.64; 95% CI: -6.26 to -1.03; p < 0.01) and at the end of follow-up (MD = -4.82; 95% CI: -8.80 to -0.85; p = 0.02). No association was detected between GLP-1 RAs and body mass index. No serious adverse events or treatment discontinuations were reported; mild gastrointestinal adverse events and nausea occurred in 88% (95% CI: 0.46-1.00) of GLP-1 RA-treated patients.
CONCLUSIONS: GLP-1 and dual GIP/GLP-1 RAs are associated with a significantly lower risk of papilledema and visual disturbances or blindness and a lower headache risk compared with standard-of-care. Additionally, GLP-1 RAs significantly reduce the monthly headache burden. Well-designed RCTs are needed to robustly evaluate the effects of GLP-1 and GIP/GLP-1 RAs in IIH, which likely extend beyond their weight-loss-inducing properties.
TRIAL REGISTRATION: PROSPERO registration ID: CRD42025650082.